Future Biosimilars: The 2025-2030 Patent Cliff and Market Entry Guide
Explore the upcoming biosimilar wave as major biologics like Keytruda and Eylea face patent expirations between 2025 and 2030. Learn about cost savings, safety, and market entry strategies.
Read Details